{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:08:31Z","timestamp":1791439711854,"version":"4.3.3"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.contraception.2020.04.012","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T11:26:16Z","timestamp":1587381976000},"page":"119-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Trends in medication abortion provision before and after the introduction of mifepristone: A study of the National Abortion Federation\u2019s Canadian member services"],"prefix":"10.1016","volume":"102","author":[{"given":"Abdiasis","family":"Yalahow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Doctoroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-5792","authenticated-orcid":false,"given":"Alice","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-203X","authenticated-orcid":false,"given":"Angel M.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2020.04.012_b0005","unstructured":"Canadian Institute of Health Information. Induced abortions reported in Canada in 2017 [Internet]. Available from: https:\/\/www.cihi.ca\/en\/induced-abortions-reported-in-canada-in-2017. [Accessed February 16, 2020]."},{"key":"10.1016\/j.contraception.2020.04.012_b0010","first-page":"e201","article-title":"First-trimester medical abortion practices in Canada: a national survey","volume":"62","author":"Guilbert","year":"2016","journal-title":"Can Fam Phys"},{"key":"10.1016\/j.contraception.2020.04.012_b0015","unstructured":"Action Canada for Sexual Health and Rights. The politics of Mifegymiso in Canada: key dates and milestones [Internet]. Available from: https:\/\/www.actioncanadashr.org\/resources\/factsheets-guidelines\/2018-11-05-politics-mifegymiso-canada-key-dates-and-milestones. [Accessed February 16, 2020]."},{"key":"10.1016\/j.contraception.2020.04.012_b0020","series-title":"Safe abortion: technical and policy guidance for health systems","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.contraception.2020.04.012_b0025","unstructured":"Health Canada. Regulatory decision summary: Mifegymiso [Internet]. Available from: https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00294. [Accessed February 16, 2020]."},{"key":"10.1016\/j.contraception.2020.04.012_b0030","unstructured":"National Abortion Federation Canada. About us [Internet]. Available from: http:\/\/www.nafcanada.org\/index.html. [Accessed February 16, 2020]."},{"key":"10.1016\/j.contraception.2020.04.012_b0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2016.04.008","article-title":"Exploring Canadian women\u2019s knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients","volume":"94","author":"Vogel","year":"2016","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2020.04.012_b0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.contraception.2020.04.007","article-title":"\u201cIt gives you autonomy over your own choices\u201d: A qualitative study of Canadian abortion patients\u2019 experiences with mifepristone and misoprostol","volume":"102","author":"LaRoche","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.04.012_b0045","unstructured":"Health Canada. Health Canada approves updates to Mifegymiso prescribing information: Ultrasound no longer mandatory [Internet]. Available from: https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2019\/69620a-eng.php. [Accessed February 16, 2020]."},{"key":"10.1016\/j.contraception.2020.04.012_b0050","unstructured":"Canadian Pharmacists Association. Women\u2019s reproductive health [Internet]. [Available from: https:\/\/www.pharmacists.ca\/education-practice-resources\/patient-care\/women-s-reproductive-health\/. [Accessed February 16, 2020]."}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078242030127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078242030127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:15:34Z","timestamp":1757880934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001078242030127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S001078242030127X"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2020.04.012","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in medication abortion provision before and after the introduction of mifepristone: A study of the National Abortion Federation\u2019s Canadian member services","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2020.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}